

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Cultivar Holdings Inc. (the "Issuer").

Trading Symbol: CSE: CULT; OTCQB: CVRHF

Number of Outstanding Listed Securities: 100,054,149

Date: April 6, 2020

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

*On March 30, 2020, the Issuer announced that it had entered into a sale agreement (the "**Sale Agreement**") with respect to its 49% interest in Cultivar JA Limited ("**Cultivar JA**"), which holds a provisional cannabis cultivation license in Jamaica.*

The Issuer's sale of its interest in Cultivar JA will allow it to eliminate its expenditures on cannabis cultivation in Jamaica, and correspondingly allocate additional capital

to its Predictmedix division, which has been making significant advancements. Predictmedix's artificial intelligence ("**AI**") powered impairment detection technology (patent pending) is currently being validated with a study of over 3,000 participants. Additionally, Predictmedix has been working towards expanding its proprietary AI technology into healthcare, specifically to screen for infectious diseases along with psychiatric disorders such as depression, dementia and Alzheimer's Disease.

Pursuant to the terms of the Sale Agreement, the Issuer's wholly-owned subsidiary, Cultivar Holdings Ltd. ("**CHL**"), agreed to sell its 49% interest in Cultivar JA and all related royalty interests to the principals of Cultivar JA in exchange for the principals of Cultivar JA agreeing to cancel 4,000,000 common shares of the Issuer owned by the principals. In addition, the principals have also agreed to terminate their right to receive an additional 500,000 common shares of the Issuer, which had been reserved for issuance upon Jamaica's Licensing Authority issuing final approval for Cultivar JA's license to cultivate, process, retail and transport cannabis.

2. Provide a general overview and discussion of the activities of management.

The Issuer continues to work towards the business disclosed in the press release dated March 30, 2020 and as described in #1 above.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

The Issuer will continue to develop Predictmedix's proprietary AI-powered impairment detection technology described in #1.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

See #1 above with respect to Cultivar JA.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

*The Sale Agreement between the Issuer, CHL, Cultivar JA, Eugene Anthony Ffolkes ("**Ffolkes**"), Sharon Annette Abrahams and Peter Abrahams (collectively, "**Abrahams**") was agreed upon on March 27, 2020. Pursuant to the Sale Agreement, Ffolkes and Abrahams each cancelled 2,000,000 common shares of the Issuer (totalling 4,000,000 Issuer common shares).*

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable.

8. Describe the acquisition of new customers or loss of customers.

Not applicable.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Not applicable.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾

Not applicable.

15. Provide details of any loans to or by Related Persons.

Not applicable.

16. Provide details of any changes in directors, officers or committee members.

Not applicable.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Issuer's large scale study for its alcohol and cannabis impairment prediction technology is progressing well. The Issuer believes that enhancing its Predictmedix division is a positive trend for the Issuer and its shareholders, and in particular, in light of the global COVID-19 pandemic.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated April 6, 2020.

Rakesh Malhotra
Name of Director or Senior Officer

/s/ "Rakesh Malhotra"
Signature

CFO
Official Capacity

Issuer Details	For Month End	Date of Report
Name of Issuer		YY/MM/DD
Cultivar Holdings Inc.	March 31, 2020	20/04/06
Issuer Address		
3000-77 King Street West		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Toronto, Ontario, M5K 1G8	N/A	(647) 889-6916
Contact Name	Contact Position	Contact Telephone No.
Dr. Rahul Kushwah	COO	(647) 889-6916
Contact Email Address	Web Site Address	
rahul.kushwahphd@gmail.com	http://cultivarholdings.com/	